MedElevator
Войти в исследования Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2011
Contact transcleral photodynamic cyclo-suppression in human eyes: a feasibility study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Charisis Spyridon K, Detorakis Efstathios T, Vitanova Vania S, Panteleontidis Vassilios A, Kounis Georgios A, Tsilimbaris Miltiadis K
Аннотация
OBJECTIVE: To evaluate the safety and efficacy of contact transcleral ciliary body photodynamic treatment (CB-PDT) with verteporfin in human eyes.
DESIGN: Prospective interventional case series.
PARTICIPANTS: Five glaucomatous blind eyes of 5 patients.
METHODS: Verteporfin (6 mg/m(2)) was infused in bolus and then the ciliary body was irradiated transclerally with a fibre optic device. Twelve spots were placed 360° and 0.5 mm behind the sclerocorneal limbus. Laser power was 80 mW and irradiation time was 3 minutes.
RESULTS: The average intraocular pressure reduction was 30% after the first month and remained below pre-treatment levels throughout a 3-month follow-up. No serious adverse events were reported.
CONCLUSIONS: CB-PDT for refractory glaucoma was safe and efficient in human eyes; larger studies are required to evaluate its possible clinical role.
DESIGN: Prospective interventional case series.
PARTICIPANTS: Five glaucomatous blind eyes of 5 patients.
METHODS: Verteporfin (6 mg/m(2)) was infused in bolus and then the ciliary body was irradiated transclerally with a fibre optic device. Twelve spots were placed 360° and 0.5 mm behind the sclerocorneal limbus. Laser power was 80 mW and irradiation time was 3 minutes.
RESULTS: The average intraocular pressure reduction was 30% after the first month and remained below pre-treatment levels throughout a 3-month follow-up. No serious adverse events were reported.
CONCLUSIONS: CB-PDT for refractory glaucoma was safe and efficient in human eyes; larger studies are required to evaluate its possible clinical role.